Evolus Reports Positive Pivotal Trial Data for Evolysse™ Sculpt Hyaluronic Acid Gel at 2025 Cosmetic Bootcamp, Marking a Major Milestone in Aesthetic Innovation Evolus, Inc. (NASDAQ: EOLS), a fast-growing performance beauty company dedicated to reshaping the aesthetic medicine landscape, announced…
Sarepta Therapeutics Restructures $700 Million in Convertible Debt, Extending Maturities and Strengthening Financial Flexibility Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine focused on rare diseases, has announced a significant refinancing transaction designed to strengthen its capital…
Sensory Cloud Reports Encouraging Phase 2a REACH Trial Results for Novel Aerosol Therapy in Refractory Chronic Cough Sensory Cloud Inc., a clinical-stage biopharmaceutical company developing first-in-class therapies targeting mechano-sensitive ion channels in the respiratory system, together with collaborators at King…
PharmaCyte Biotech Strengthens Financial Position with $7 Million Private Placement Led by Existing Investors Financing provides strategic capital infusion to support corporate initiatives, enhance balance sheet, and advance long-term value creation plans PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the…
IntegriChain Appoints New Chief AI and Technology Officer to Lead Next Era of Innovation, Automation, and Customer Experience in Life Sciences IntegriChain, a recognized market leader in net revenue optimization technology and commercial data insights for the life sciences industry,…
TriSalus Life Sciences Announces Strong Q2 2025 Results, Affirms Full-Year Outlook, and Advances Strategic Focus on Liver-Directed Therapies TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company pioneering innovative delivery solutions for treating solid tumors, today reported its financial results…
Quince Therapeutics Announces Major Clinical and Corporate Milestones Alongside Q2 2025 Financial Results Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to harnessing a patient’s own biology for the treatment of rare and underserved diseases, has delivered a…
Enanta Pharmaceuticals Reports Fiscal Third Quarter 2025 Results and Provides Pipeline Progress Update Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule drugs for viral infections and immunological diseases, today announced…
Equillium Secures Up to $50 Million in Private Placement Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, Into Clinical Development Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator dedicated to developing novel therapies for severe autoimmune and inflammatory disorders,…
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results, Advances Tecarfarin Clinical Development, and Strengthens Strategic Position in Anticoagulation Market Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company dedicated to developing next-generation anticoagulation therapies that address significant unmet needs in patient…
Rocket Pharmaceuticals Announces Second Quarter 2025 Results, Reshapes Strategic Focus Around Cardiovascular Gene Therapy Platform, and Advances Late-Stage Pipeline Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company developing a sustainable portfolio of genetic therapies for rare disorders…
Spine BioPharma Releases Phase 3 Data for SB-01 in Chronic Low Back Pain: Trial Misses Primary Endpoint Amid Strong Safety and Subgroup Efficacy Signals Spine BioPharma, Inc., a clinical-stage biopharmaceutical company advancing non-surgical treatments for spine-related pain, has announced topline…
